| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
108,674,000 |
| Market
Cap: |
42.88(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2298 - $2.31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 707 |
| Guru Rank Value : 1.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
816,825 |
816,825 |
| Total Buy Value |
$0 |
$0 |
$194,885 |
$194,885 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
4 |
4 |
| Total Shares Sold |
211,204 |
267,396 |
419,842 |
591,605 |
| Total Sell Value |
$130,313 |
$170,773 |
$340,560 |
$980,941 |
| Total People Sold |
5 |
5 |
6 |
9 |
| Total Sell Transactions |
5 |
10 |
23 |
41 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dupont Jakob |
EVP, Head of R&D |
• – – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
53,879 |
100,129 |
|
- |
|
| Murugan Amar |
SVP, GC & Secretary |
• – – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
41,756 |
97,425 |
|
- |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,715 |
143,384 |
|
- |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2021-02-08 |
4 |
AS |
$20.39 |
$79,236 |
D/D |
(3,886) |
105,669 |
|
-28% |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2021-02-08 |
4 |
AS |
$20.39 |
$35,866 |
D/D |
(1,759) |
130,546 |
|
-28% |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2021-01-15 |
4 |
AS |
$18.84 |
$131,880 |
D/D |
(7,000) |
109,555 |
|
-26% |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2021-01-15 |
4 |
OE |
$12.15 |
$42,525 |
D/D |
3,500 |
116,555 |
|
- |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2020-12-16 |
4 |
AS |
$23.08 |
$161,735 |
D/D |
(7,000) |
113,055 |
|
-36% |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2020-12-16 |
4 |
OE |
$12.15 |
$42,525 |
D/D |
3,500 |
120,055 |
|
- |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2020-11-17 |
4 |
AS |
$19.77 |
$32,588 |
D/D |
(1,648) |
116,555 |
|
-30% |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2020-11-17 |
4 |
AS |
$19.77 |
$29,048 |
D/D |
(1,469) |
132,061 |
|
-30% |
|
| Touchon Pascal |
President and CEO |
• • – |
2020-11-17 |
4 |
AS |
$19.77 |
$93,254 |
D/D |
(4,716) |
255,321 |
|
-30% |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2020-11-13 |
4 |
AS |
$18.36 |
$138,688 |
D/D |
(7,500) |
118,203 |
|
-18% |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2020-11-13 |
4 |
OE |
$12.15 |
$42,525 |
D/D |
3,500 |
125,703 |
|
- |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2020-08-18 |
4 |
AS |
$12.09 |
$20,287 |
D/D |
(1,678) |
122,203 |
|
72% |
|
| Touchon Pascal |
President and CEO |
• • – |
2020-08-18 |
4 |
AS |
$12.09 |
$58,117 |
D/D |
(4,807) |
260,037 |
|
72% |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2020-08-18 |
4 |
AS |
$12.09 |
$18,087 |
D/D |
(1,496) |
133,530 |
|
72% |
|
| Touchon Pascal |
President and CEO |
• • – |
2020-06-25 |
4 |
AS |
$12.92 |
$156,784 |
D/D |
(12,135) |
264,844 |
|
-1% |
|
| Dobmeier Eric |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
28,000 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
100,818 |
|
- |
|
| Baynes Roy D. |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
12,000 |
|
- |
|
| Heiden William K |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
20,500 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
33,854 |
|
- |
|
| Seidenberg Beth C |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
27,189 |
|
- |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2020-06-09 |
4 |
AS |
$10.18 |
$39,946 |
D/D |
(3,924) |
135,026 |
|
32% |
|
736 Records found
|
|
Page 7 of 30 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.03 (7.04%) 
